Liao Kuan-Fu, Cheng Kao-Chi, Lin Cheng-Li, Lai Shih-Wei
College of Medicine, Tzu Chi University, Hualien 970, Taiwan - Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung 427, Taiwan - Graduate Institute of Integrated Medicine, China Medical University, Taichung 404, Taiwan.
College of Medicine, China Medical University, Taichung 404, Taiwan - Department of Family Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Biomedicine (Taipei). 2017 Mar;7(1):4. doi: 10.1051/bmdcn/2017070104. Epub 2017 Mar 3.
The aim of this study was to explore the association between etodolac use and acute in Taiwan.
We designed a case-control study using the database of Taiwan's National Health Insurance.
In all, 7577 subjects aged 20 years or older with newly diagnosed acute pancreatitis were defined as cases, and 27032 sex-matched and age-matched subjects without acute pancreatitis were defined as controls. The period considered for this study was from 1998 to 2011. For the study, never having used etodolac is defined as a subject never receiving a prescription for etodolac. Active use of etodolac is defined as a subject receiving at least 1 prescription for etodolac within 7 days of the date of their being diagnosed with acute pancreatitis. Non-active use of etodolac is defined as a subject not receiving a prescription for etodolac within 7 days but receiving at least 1 prescription for etodolac ≥ 8 days before the date of their being diagnosed with acute pancreatitis.
The association between etodolac use and acute pancreatitis was estimated by using the multivariable unconditional logistic regression model.
After correcting for covariates, the adjusted odds ratio of acute pancreatitis was 3.78 for subjects with active use of etodolac (95% confidence interval 1.11, 12.9), compared with subjects who never used etodolac. The adjusted odds ratio decreased to 1.18 for subjects with non-active use of etodolac (95% confidence interval 0.38, 3.67), but that was without statistical significance.
There could be an association between active use of etodolac and acute pancreatitis. Clinicians should take into account the possibility of etodolac-associated acute pancreatitis when patients currently using etodolac present with acute pancreatitis with an unknown cause.
本研究旨在探讨在台湾地区使用依托度酸与急性胰腺炎之间的关联。
我们利用台湾国民健康保险数据库设计了一项病例对照研究。
总共7577名20岁及以上新诊断为急性胰腺炎的受试者被定义为病例组，27032名性别和年龄匹配且无急性胰腺炎的受试者被定义为对照组。本研究考虑的时间段为1998年至2011年。对于本研究，从未使用依托度酸被定义为受试者从未接受过依托度酸处方。积极使用依托度酸被定义为受试者在被诊断为急性胰腺炎之日起7天内至少接受过1次依托度酸处方。非积极使用依托度酸被定义为受试者在7天内未接受依托度酸处方，但在被诊断为急性胰腺炎之日前≥8天至少接受过1次依托度酸处方。
使用多变量无条件逻辑回归模型估计依托度酸使用与急性胰腺炎之间的关联。
校正协变量后，积极使用依托度酸的受试者发生急性胰腺炎的校正比值比为3.78（95%置信区间1.11，12.9），与从未使用依托度酸的受试者相比。非积极使用依托度酸的受试者校正比值比降至1.18（95%置信区间0.38，3.67），但无统计学意义。
积极使用依托度酸与急性胰腺炎之间可能存在关联。当目前正在使用依托度酸的患者出现病因不明的急性胰腺炎时，临床医生应考虑依托度酸相关性急性胰腺炎的可能性。
